 |
|
Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular DysfunctionA Quantitative Review of Data From Randomized Clinical Trials
Christopher O. Phillips, MD, MPH;
Amir Kashani, MS, MD;
Dennis K. Ko, MD;
Gary Francis, MD;
Harlan M. Krumholz, MD, SM
Arch Intern Med. 2007;167(18):1930-1936.
Background We performed a meta-analysis of randomized controlled trials to assess ongoing concerns about the safety profile of combination angiotensin II receptor blockers (ARBs) plus angiotensin-converting enzyme (ACE) inhibitors in symptomatic left ventricular dysfunction.
Methods MEDLINE (January 1966–December 2006) and Web sites for the National Institute of Health Clinical Trials and the Food and Drug Administration were searched for eligible RCTs that included 500 or more subjects, had a follow-up of 3 months or longer, and reported adverse effects. We used a random effects model to calculate the relative risk (RR) and 95% confidence interval (CI) for the following outcome measures: medication discontinuations because of adverse effects, worsening renal function (an increase in serum creatinine level of > 0.5 mg/dL [to convert to micromoles per liter, multiply by 88.4]), hyperkalemia (serum potassium level > 5.5 mEq/L [to convert to millimoles per liter, multiply by 1]), and symptomatic hypotension.
Results Four studies (N = 17 337; mean follow-up, 25 months [range, 11-41 months]) were selected. Combination ARB plus ACE inhibitor vs control treatment that included ACE inhibitors was associated with significant increases in medication discontinuations because of adverse effects in patients with chronic heart failure (RR, 1.38 [95% CI, 1.22-1.55]) or in patients with acute myocardial infarction with symptomatic left ventricular dysfunction (RR, 1.17 [95% CI, 1.03-1.34]), and for both conditions there were significant increases in worsening renal function (RR, 2.17 [95% CI, 1.59-2.97] and RR, 1.61 [95% CI, 1.31-1.98], respectively), hyperkalemia (RR, 4.87 [95% CI, 2.39-9.94] and RR, 1.33 [95% CI, 0.90-1.98], respectively; the latter was not significant), and symptomatic hypotension (RR, 1.50 [95% CI, 1.09-2.07], and RR, 1.48 [95% CI, 1.33-3.18], respectively).
Conclusion Combination ARB plus ACE inhibitor therapy in subjects with symptomatic left ventricular dysfunction was accompanied by marked increases in adverse effects.
Author Affiliations: Department of General Internal Medicine and Section of Hospital Medicine, The Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (Dr Phillips); Yale University School of Medicine and Yale–New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Connecticut (Drs Kashani and Krumholz); Division of Cardiology, The Cleveland Clinic (Dr Francis); and Division of Cardiology, Schulich Hearth Center, Sunnybrook Health Sciences Centre, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada (Dr Ko).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Review: The therapeutic role of RAS blockade in chronic heart failure
Werner and Bohm
Therapeutic Advances in Cardiovascular Disease 2008;2:167-177.
ABSTRACT
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
The ONTARGET Investigators
NEJM 2008;358:1547-1559.
ABSTRACT
| FULL TEXT
What's new in hypertension 2007?
Mann
Nephrol Dial Transplant 2008;23:466-470.
FULL TEXT
Combination ACE-Inhibitor and Angiotensin-Receptor Blocker Therapy: A Review of Safety Data
JWatch General 2007;2007:1-1.
FULL TEXT
Combination ACE-inhibitor and Angiotensin-Receptor Blocker Therapy: A Review of Safety Data
Journal Watch Cardiology 2007;2007:1-1.
FULL TEXT
|
